Related references
Note: Only part of the references are listed.Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases
Andrew M. Baschnagel et al.
SCIENTIFIC REPORTS (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
Mu-Yan Cai et al.
CELL REPORTS (2020)
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Biagio Ricciuti et al.
CLINICAL CANCER RESEARCH (2020)
Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas
Michael M. Fisher et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer
Gopika SenthilKumar et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd et al.
ONCOGENE (2020)
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Rui-Xue Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial
Alexander Sun et al.
JAMA ONCOLOGY (2019)
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
Christopher B. Jackson et al.
CANCER RESEARCH (2019)
Nonesmall-cell Lung Cancer With Brain Metastasis at Presentation
Saiama N. Waqar et al.
CLINICAL LUNG CANCER (2018)
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Xinyi Tu et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Magnus T. Dillon et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC
Lars F. Petersen et al.
ONCOTARGET (2017)
Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto et al.
JAMA ONCOLOGY (2017)
Statistical colour models: an automated digital image analysis method for quantification of histological biomarkers
Jie Shu et al.
BIOMEDICAL ENGINEERING ONLINE (2016)
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer
Katarzyna B. Leszczynska et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations
Helen B. Stone et al.
TRANSLATIONAL ONCOLOGY (2016)
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer
Xiaolan Feng et al.
ONCOTARGET (2016)
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
Anika Maria Weber et al.
ONCOTARGET (2016)
ATM protein is deficient in over 40% of lung adenocarcinomas
Liza C. Villaruz et al.
ONCOTARGET (2016)
Fitting Linear Mixed-Effects Models Using lme4
Douglas Bates et al.
JOURNAL OF STATISTICAL SOFTWARE (2015)
Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
Elda Grabocka et al.
CANCER CELL (2014)
ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
Rozenn Josse et al.
CANCER RESEARCH (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Amy B. Hall et al.
ONCOTARGET (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
I. M. Pires et al.
BRITISH JOURNAL OF CANCER (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
Jean-Damien Charrier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
ATR signaling at a glance
Bunsyo Shiotani et al.
JOURNAL OF CELL SCIENCE (2009)
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)
Jonathan P. S. Knisely et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
ATR: an essential regulator of genome integrity
Karlene A. Cimprich et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Neuropsychological testing and biomarkers in the management of brain metastases
Andrew Baschnagel et al.
RADIATION ONCOLOGY (2008)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases
JH Suh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
